GlassScriptPhysician profile
Emily R Todd
NPI 1447813837
$7,037.52
in general payments reported to CMS, 2019-2025
27 companies · $846 in 2025
The $846 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,884 · 2022: $1,889 · 2023: $1,145 · 2024: $1,273 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950 · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.06 |
| Education | $314.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,571.26 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $779.61 | 2021-2025 | Dupixent |
| Allergan, INC. | $723.94 | 2022 | |
| Genzyme Corporation | $518.81 | 2021-2025 | |
| Janssen Biotech, INC. | $507.29 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $491.10 | 2021-2025 | Ilumya |
| Amgen INC. | $365.47 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $273.32 | 2021-2024 | Olumiant, Taltz, Zepbound |
| Pfizer INC. | $243.70 | 2021-2025 | |
| Incyte Corporation | $215.60 | 2021-2023 | Opzelura |
| Galderma Laboratories, L.P. | $186.37 | 2021-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $178.62 | 2024 | Sotyktu |
| Leo Pharma INC. | $176.24 | 2022-2025 | Adbry |
| Dermavant Sciences, INC. | $170.89 | 2023-2024 | Vtama |
| Ucb, INC. | $148.27 | 2023-2025 | Bimzelx, Cimzia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $106.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $100.67 | 2021 | |
| Almirall LLC | $80.40 | 2021-2024 | Klisyri |
| Epi Health, LLC | $47.22 | 2021 | |
| Biofrontera INC. | $28.91 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $21.86 | 2023 | Idacio |
| Dermira, INC. | $20.85 | 2021 | |
| Verrica Pharmaceuticals INC. | $20.45 | 2023 | Ycanth |
| Vyne Pharmaceuticals INC. | $15.92 | 2021 | |
| Journey Medical Corporation | $14.77 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.62 | 2021 | |
| Arcutis Biotherapeutics, INC. | $14.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.